Respiratory Syncytial Virus (RSV) Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis, ADMA Biologics, Enanta Pharma, Merck, Janssen

The Respiratory Syncytial Virus (RSV) Market size in the 7MM was observed to be ~USD 1,200 million in 2022, which is expected to grow by 2032. As per DelveInsight, the Respiratory Syncytial Virus Market is anticipated to evolve immensely in the coming years owing to the increase in the patient pool and the expected entry of emerging therapies.

DelveInsight's "Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Respiratory Syncytial Virus Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Respiratory Syncytial Virus therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Respiratory Syncytial Virus treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Respiratory Syncytial Virus (RSV): An Overview
Respiratory syncytial virus (RSV) is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human RSV, bovine RSV, and murine pneumonia virus.

Two major antigenic subtypes of human RSV (A and B) are determined mainly by antigenic drift and duplications in RSV-G sequences but accompanied by genome-wide sequence divergence, including within RSV-F.

The virion consists of eight structural proteins. Three proteins are associated with the nucleocapsid and include nucleoprotein (N), phosphoprotein (P), and polymerase or large protein (L). The other five viral proteins are contained within the virus envelope and include nonglycosylated matrix protein (M), M2, fusion protein (F), glycoprotein (G), and short hydrophobic protein (SH). RSV lacks hemagglutinin and neuraminidase activity. The viral genome consists of a linear, single-stranded, negative-sense, nonsegmented RNA (~15.2 kb).

Respiratory Syncytial Virus (RSV) Market Key Facts
• The United States constituted ~71% of the total Respiratory Syncytial Virus market share, followed by EU4 and the UK (23%), and Japan (6%).
• In 2022, palivizumab generated a revenue of around USD 400 million in the 7MM, and its revenue is expected to decrease over the years due to the upcoming therapies.
• In 2022, the total incident cases of Respiratory Syncytial Virus in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
• Total incident cases of Respiratory Syncytial Virus were highest in those below 5 years, followed by 65 years and above, and the least number of cases were found in the 5 to 64 years age group.
• The United States comprised ~58% of the total incident Respiratory Syncytial Virus cases in the 7MM in 2022.
• EU4, the UK, and Japan contributed ~30% and 12% to the total incident pool of Respiratory Syncytial Virus in 2022.

Discover How Respiratory Syncytial Virus Market Will Grow by 2032:
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Respiratory Syncytial Virus (RSV) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Respiratory Syncytial Virus therapies in the market. It also provides a detailed assessment of the Respiratory Syncytial Virus market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Respiratory Syncytial Virus drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Respiratory Syncytial Virus (RSV) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Respiratory Syncytial Virus patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Respiratory Syncytial Virus Epidemiology Segmented as -
• Total Incident Cases of Respiratory Syncytial Virus (RSV) in the 7MM [2019-2032]
• Age-specific Incident Cases of Respiratory Syncytial Virus (RSV) in the 7MM [2019-2032]

Get Key Insights Into the Evolving Respiratory Syncytial Virus Epidemiology Trends @
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Respiratory Syncytial Virus (RSV) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory Syncytial Virus market or expected to be launched during the study period. The analysis covers the market share by Respiratory Syncytial Virus drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Respiratory Syncytial Virus Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Respiratory Syncytial Virus (RSV) Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Respiratory Syncytial Virus (RSV). Currently, GlaxoSmithKline is leading the therapeutics market with its Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage of clinical development.

Leading Companies in the Respiratory Syncytial Virus (RSV) Therapeutics Market Include
GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc. Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and many more.

Emerging and Marketed Respiratory Syncytial Virus (RSV) Therapies Covered in the Report Include
• Nirsevimab (MEDI-8897): MedImmune
• mRNA-1345: Moderna
• Sisunatovir: ReViralRespiratory Syncytial ViruspreF (PF-06928316): Pfizer
• Respiratory Syncytial VirusPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
• SYNAGIS (palivizumab): Swedish Orphan Biovitrum AB (SOBI)
And Many Others

Learn More About the Emerging Therapies & Key Companies in the Respiratory Syncytial Virus Therapeutics Market:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Respiratory Syncytial Virus Competitive Intelligence Analysis
4. Respiratory Syncytial Virus Market Overview at a Glance
5. Respiratory Syncytial Virus Background and Overview
6. Respiratory Syncytial Virus Patient Journey
7. Respiratory Syncytial Virus Epidemiology and Patient Population
8. Respiratory Syncytial Virus Treatment Algorithm, Current Treatment, and Medical Practices
9. Respiratory Syncytial Virus Unmet Needs
10. Key Endpoints of Respiratory Syncytial Virus Treatment
11. Respiratory Syncytial Virus Marketed Products
12. Respiratory Syncytial Virus Emerging Therapies
13. Respiratory Syncytial Virus Seven Major Market Analysis
14. Attribute Analysis
15. Respiratory Syncytial Virus Market Outlook (7 major markets)
16. Respiratory Syncytial Virus Access and Reimbursement Overview
17. KOL Views on the Respiratory Syncytial Virus Market.
18. Respiratory Syncytial Virus Market Drivers
19. Respiratory Syncytial Virus Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Acute Ocular Pain Market
https://www.delveinsight.com/report-store/acute-ocular-pain-market

Adenoid Cystic Carcinoma Market
https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market

Frontotemporal Dementia Market
https://www.delveinsight.com/report-store/frontotemporal-dementia-market

Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market

Dense Deposit Disease Market
https://www.delveinsight.com/report-store/dense-deposit-disease-market

High-Grade Glioma Market
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market

Implantable Infusion Pumps Global Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market

Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market

Post-Polycythemia Vera Myelofibrosis Market
https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-market

Postmyocardial Infarction Syndrome Market
https://www.delveinsight.com/report-store/postmyocardial-infarction-syndrome-market

Acute ischemic stroke (AIS) Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market

Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market

Conductive Hearing Loss Market
https://www.delveinsight.com/report-store/conductive-hearing-loss-market

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

Ductal Carcinoma in Situ Market
https://www.delveinsight.com/report-store/ductal-carcinoma-in-situ-market

Electroencephelographs (EEG) Pipeline Insight
https://www.delveinsight.com/report-store/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape

Encephalomyelitis Market
https://www.delveinsight.com/report-store/encephalomyelitis-market

Graves Ophthalmopathy Market
https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

Graves Orbitopathy Market
https://www.delveinsight.com/report-store/graves-orbitopathy-market

Hemophagocytic Lymphohistiocytosis Market
https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/recurrent-head-and-neck-cancer-squamous-cell-carcinoma-market

Tenosynovitis Market
https://www.delveinsight.com/report-store/tenosynovitis-market

Urticaria Or Hives Market
https://www.delveinsight.com/report-store/urticaria-or-hives-market

Dermal Regeneration Matrix Market
https://www.delveinsight.com/report-store/dermal-regeneration-matrix-market

Glioma Market
https://www.delveinsight.com/report-store/glioma-market

Angelman Syndrome Market
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast

Chronic Pancreatitis (CP) Market
https://www.delveinsight.com/report-store/chronic-pancreatitis-market

Follicular Lymphoma Market
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights

Hereditary Spastic Paraplegias Market
https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market

Decompensated Cirrhosis Market
https://www.delveinsight.com/report-store/decompensated-cirrhosis-market

Hepatitis D Market
https://www.delveinsight.com/report-store/hepatitis-d-market

Nontuberculous Mycobacterial (NTM) Infections Market
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.